Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split [Yahoo! Finance]
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ:AMEX Investor Relations:
ir.citiuspharma.com
Company Research
Source: Yahoo! Finance
will be executing a reverse stock split of its common stock, par value per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25, 2024 . The Company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on November 26, 2024 , under the Company's existing trading symbol "CTXR" with the new CUSIP number 17322U306. The Reverse Stock Split is intended to increase the per share trading price of Citius Pharma's common stock to regain compliance with the minimum bid price requirement of per share of common stock for continued listing on the Nasdaq Capital Market. Under Section 78.207 of the Nevada Revised Statutes, the Company may decre
Show less
Read more
Impact Snapshot
Event Time:
CTXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTXR alerts
High impacting Citius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CTXR
News
- Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitPR Newswire
- Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingPR Newswire
- Citius Pharmaceuticals Announces $3 Million Registered Direct OfferingPR Newswire
- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIRâ„¢ in Cancer Patients with Recurrent Solid TumorsPR Newswire
CTXR
Earnings
- 8/12/24 - Miss
CTXR
Analyst Actions
- 11/12/24 - HC Wainwright
CTXR
Sec Filings
- 11/18/24 - Form 8-K
- 11/18/24 - Form 424B5
- 11/13/24 - Form 8-K
- CTXR's page on the SEC website